Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer

Figure 3

Time-dependent ROC curves at 1 year of the CSC gene signature, Gleason score, T stage, and N stage (a) in the entire TCGA database; decision curve analysis at 1 year for the CSC gene signature, Gleason score, and the combined model (b). The -axis measures the net benefit.

(a)

(b)